低分子肝素治疗脑梗死

Low-molecular Heparin (Reviparin) Treating Acute Cerebral Infarction

目的 :评价低分子肝素 (诺易平 ,Reviparin)治疗脑梗死的疗效和安全性。方法 :130例脑梗死患者均发病 4 8h内 ,分为治疗组和对照组 ,均用香丹注射液作基础治疗 ,治疗组 80例同时加用诺易平腹壁皮下注射 ,每日 2次 ,连续 10d。 2组治疗前及治疗 10及 30d时采用中风评分法进行神经功能缺损评分 ;监测血常规及凝血指标 ;评定临床疗效及不良反应等。结果 :2组治疗后神经功能缺损评分与治疗前比较均有改善。治疗组神经功能缺损评分在治疗第 10d时与治疗前比较差异有显著性 (P <0 .0 5 ) ,对照组差异无显著性 (P >0 .0 5 ) ;治疗第 30d时治疗组与治疗前比较P <0 .0 1,对照组P <0 .0 5。 2组间比较差异有显著性 (P <0 .0 5 )。临床疗效评定 ,治疗组总有效率 88.8% ,明显优于对照组的 6 0 % (P <0 .0 1)。各项凝血指标 2组治疗前后差异均无显著性 (P >0 .0 5 ) ,未发现出血倾向。结论 :诺易平治疗脑梗死安全有效 ,是理想的抗凝剂。

Objective: To study the effect and safety of low molecular heparin (Reviparin) in the treatment of acute cerebral infarction.Methods: All patients with acute cerebral infarction within 48 h of stroke onset were treated with Xiang Dan Injection as basic treatment. Eighty patients were treated with 'add on' Reviparin. There were 50 randomized patients as control. Reviparin (1432 anti factor Xa IU, twice a day) was given subcutaneously for 10 days. Functional outcome at one month after the stroke was assessed according to China Stroke Scale. Results: The total improvement rate of cerebral infarction treated with Reviparin ( 88.8% ) was significantly greater than in the control group (60%, P < 0.01 ). No hemorrhage tendency was found. Conclusion: Reviparin in the treatment of acute cerebral infarction is effective and safe.